Article Text

Download PDFPDF

126 A 10 year clinico-pathological study of residual/recurrent borderline ovarian tumours in young females undergoing fertility-preserving surgery
  1. S Toomey,
  2. M Basha Mohamed and
  3. R Arora
  1. University College London Hospitals NHS Foundation Trust, UK


Introduction Borderline ovarian tumours (BOT) have a good prognosis with a 5–8% recurrence rate. Although complete staging is the standard surgical treatment; when they occur in younger women, fertility preservation is important. Since the effect of fertility-preserving surgery on recurrence remains inconclusive, in the present study we examined the clinicopathological factors in residual/recurrent BOT.

Methods BOT diagnosed between 2010 and 2020 were retrieved using electronic records for women <40 years. Clinicopathological features of residual/recurrent BOT during this period were analysed.

Results In total, 74 BOT cases were reviewed which consisted of 42 (56.8%) serous BOT, 29 (39.2%) mucinous BOT and 3 (4.1%) seromucinous BOT.

Amongst the 13 residual/recurrent BOT, all but one were serous BOT. More than half of residual/recurrent BOT had normal CA125 at presentation. The mean age was similar to the non-recurrent BOTs. Laparoscopic cystectomy was the most common initial treatment. Bilateral tumours were seen at initial surgery in 3/13 (23.1%). The time to residual/recurrent tumour ranged from 1 to 96 months. The residual/recurrent tumours were seen in the same ovary in 3/13 (23.1%), in opposite ovary in 5/13 (38.5%) and at extraovarian sites in 5/13 (38.5%). Only 2 of the 13 cases showed focal micropapillary pattern. Cytology samples were examined in 7 cases and 5 of these reported presence of epithelial cells. Majority of residual/recurrent BOT were stage 1 at initial diagnosis. All but 2 patients are currently disease free.

Conclusions Our study highlights clinicopathological factors associated with residual/recurrent BOT in young females undergoing fertility-preserving surgery.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.